AN
ANRO
Alto Neuroscience, Inc.
$21.02
+1.15%
$729.3M
No data for this timeframe.
Vol
Market Cap$729.3M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (88%)
Inst. Holders8 funds
Inst. Value$30.3M
Inst. Activity4 buys / 0 sells
SEC Reports5
Recent Activity
May 14, 2026
Insider
Etkin Amit sold 400,000 shares
PRESIDENT AND CEO @ $0.00 ($0.00)
May 13, 2026
SEC
Alto Neuroscience reported Q1 2026 results: net loss of $26.2M ($-0.80/share) vs $-15.2M ($-0.56/share) a year ago, with
8-K — Impact 6/10
May 12, 2026
Insider
Manji Husseini sold 10,958 shares
Director @ $0.00 ($0.00)
May 12, 2026
Insider
Cox Christopher Nixon sold 10,958 shares
Director @ $0.00 ($0.00)
Apr 21, 2026
SEC
Alto Neuroscience's shelf registration (Form S-3) has become effective, allowing selling stockholders to offer up to 8,4
EFFECT — Impact 3/10
Apr 10, 2026
SEC
Alto Neuroscience is filing a shelf registration (S-3) to allow selling stockholders to resell up to 6,000,000 shares, i
S-3 — Impact 3/10
Inst.
RENAISSANCE TECHNOLOGIES LLC — ADD
97,399 shares ($1.7M)
Inst.
CHARLES SCHWAB INVESTMENT MANAGEMENT — NEW
17,064 shares ($303.7K)
Price Targets
$35.34
+68.1% upside
Strong Buy
Current $21.02
Low $24.00
Median $35.00
High $50.00
10 analysts
$24.00
$50.00
Analyst Ratings
7Strong Buy
7Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 18, 2026 | Baird | MAINTAIN | Outperform → Outperform |
| May 14, 2026 | Wedbush | MAINTAIN | Neutral → Neutral |
| May 11, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Apr 22, 2026 | Chardan Capital | MAINTAIN | Buy → Buy |
| Apr 2, 2026 | Baird | MAINTAIN | Outperform → Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.71 ▼ -41.5% | $-0.96 — $-0.57 | 4 | |
| Next Q | $-0.76 ▼ -37.7% | $-1.09 — $-0.60 | -46% YoY | 4 |
| Current FY | $-3.10 ▼ -47.5% | $-3.72 — $-2.58 | 3 | |
| Next FY | $-2.94 ▼ -29.1% | $-3.29 — $-2.23 | 5% YoY | 4 |
Latest Reports
MIXED
8-K
6/10
Alto Neuroscience reported Q1 2026 results: net loss of $26.2M ($-0.80/share) vs $-15.2M ($-0.56/share) a year ago, with
May 13, 2026
NEUTRAL
EFFECT
3/10
Alto Neuroscience's shelf registration (Form S-3) has become effective, allowing selling stockholders to offer up to 8,4
Apr 21, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $24.3M | — |
| TWO SIGMA INVESTMENTS, LP | $2.5M | DOUBLED |
| RENAISSANCE TECHNOLOGIES LLC | $1.7M | ADD |
| MORGAN STANLEY | $1.2M | ADD |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $303.7K | NEW |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 14, 2026 | Etkin Amit | G | $0.00 |
| May 12, 2026 | Manji Husseini | A | $0.00 |
| May 12, 2026 | Cox Christopher | A | $0.00 |
| May 12, 2026 | York Gwill | A | $0.00 |
| May 12, 2026 | Sanchez Ramiro | A | $0.00 |
8 institutional holders with $30.3M total value (1,704,439 shares) as of 2025-Q4. Top holders: VANGUARD, TWO, RENAISSANCE. Net buying activity: 4 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 1,365,847 | $24.3M | 80.1% | — |
| 2 | TWO SIGMA INVESTMENTS, LP | 140,317 | $2.5M | 8.2% | DOUBLED +160.6% |
| 3 | RENAISSANCE TECHNOLOGIES LLC | 97,399 | $1.7M | 5.7% | ADD +28.5% |
| 4 | MORGAN STANLEY | 65,581 | $1.2M | 3.8% | ADD +38.1% |
| 5 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 17,064 | $303.7K | 1.0% | NEW |
| 6 | BANK OF AMERICA CORP /DE/ | 11,092 | $197.4K | 0.7% | DOUBLED +8845.2% |
| 7 | FMR LLC | 6,374 | $113.5K | 0.4% | NEAR_EXIT -99.3% |
| 8 | WELLS FARGO & COMPANY/MN | 765 | $13.6K | 0.0% | NEW |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | ADD | 75,772 | 97,399 | +28.5% | $1.7M | 2025-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 17,064 | — | $303.7K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 124 | 11,092 | +8845.2% | $197.4K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | NEW | — | 765 | — | $13.6K | 2025-Q4 |
| UBS Group AG | TRIM | 428,216 | 139,031 | -67.5% | $558.9K | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 44,735 | 116,579 | +160.6% | $468.6K | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 34,700 | 75,772 | +118.4% | $304.6K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 945 | 124 | -86.9% | $498.00 | 2025-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | EXIT | 115,263 | 0 | -100.0% | $0.00 | 2025-Q3 |
| MORGAN STANLEY | ADD | 46,807 | 64,630 | +38.1% | $142.2K | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | ADD | 26,142 | 44,735 | +71.1% | $98.4K | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 34,700 | — | $76.3K | 2025-Q2 |
| FMR LLC | NEAR_EXIT | 1,272,686 | 8,297 | -99.3% | $18.3K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 11,858 | 945 | -92.0% | $2.1K | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | NEAR_EXIT | 11,237 | 351 | -96.9% | $772.00 | 2025-Q2 |
| CITADEL ADVISORS LLC | TRIM | 1,005,186 | 529,589 | -47.3% | $1.1M | 2025-Q1 |
| UBS Group AG | ADD | 402,397 | 510,210 | +26.8% | $1.1M | 2025-Q1 |
| MORGAN STANLEY | NEAR_EXIT | 202,641 | 46,807 | -76.9% | $101.1K | 2025-Q1 |
| CITADEL ADVISORS LLC | DOUBLED | 42,700 | 1,005,186 | +2254.1% | $4.3M | 2024-Q4 |
| UBS Group AG | DOUBLED | 35,008 | 402,397 | +1049.4% | $1.7M | 2024-Q4 |
| MORGAN STANLEY | DOUBLED | 76,161 | 202,641 | +166.1% | $857.2K | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 7,850 | 10,989 | +40.0% | $46.5K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 186,968 | — | $2.1M | 2024-Q3 |
| MORGAN STANLEY | DOUBLED | 26,323 | 76,161 | +189.3% | $871.3K | 2024-Q3 |
8 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 14, 2026 | Etkin Amit | PRESIDENT AND CEO | G | 400,000 | $0.00 | $0.00 |
| May 12, 2026 | Manji Husseini | Director | A | 10,958 | $0.00 | $0.00 |
| May 12, 2026 | Cox Christopher Nixon | Director | A | 10,958 | $0.00 | $0.00 |
| May 12, 2026 | York Gwill | Director | A | 10,958 | $0.00 | $0.00 |
| May 12, 2026 | Sanchez Ramiro | Director | A | 10,958 | $0.00 | $0.00 |
| Mar 1, 2026 | Etkin Amit | PRESIDENT AND CEO | F | 6,227 | $19.69 | $122.6K |
| Mar 1, 2026 | Smith Nicholas Conrad | CHIEF FINANCIAL OFFICER & CBO | F | 2,806 | $19.69 | $55.3K |
| Feb 11, 2026 | Hanley Jr. Michael Conick | CHIEF OPERATING OFFICER | A | 131,000 | $0.00 | $0.00 |
| Feb 11, 2026 | Smith Nicholas Conrad | CHIEF FINANCIAL OFFICER & CBO | A | 200,000 | $0.00 | $0.00 |
| Feb 11, 2026 | Savitz Adam | CHIEF MEDICAL OFFICER | A | 124,000 | $0.00 | $0.00 |
| Feb 11, 2026 | Etkin Amit | PRESIDENT AND CEO | A | 306,000 | $0.00 | $0.00 |
5 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 1 mixed, 3 neutral. Avg impact: 4.2/10.
MIXED
8-K
6/10
Alto Neuroscience reported Q1 2026 results: net loss of $26.2M ($-0.80/share) vs $-15.2M ($-0.56/sha
May 13, 2026
NEUTRAL
EFFECT
3/10
Alto Neuroscience's shelf registration (Form S-3) has become effective, allowing selling stockholder
Apr 21, 2026
NEUTRAL
S-3
3/10
Alto Neuroscience is filing a shelf registration (S-3) to allow selling stockholders to resell up to
Apr 10, 2026
NEUTRAL
DEFA14A
3/10
Alto Neuroscience, Inc. (ANRO) is holding its 2026 Annual Meeting, where shareholders are being aske
Mar 26, 2026
BULLISH
INST-CLUSTER
6/10
Three major passive institutions — Morgan Stanley, Wells Fargo, and UBS — significantly increased th
Feb 28, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (88% buy). Based on 16 analysts: 7 strong buy, 7 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$35.34 mean target
+68.1% upside
Strong Buy (1.18)
$24.00 Low
$50.00 High
| Metric | Value |
|---|---|
| Current Price | $21.02 |
| Target Low | $24.00 |
| Target Mean | $35.34 |
| Target Median | $35.00 |
| Target High | $50.00 |
| # Analysts | 10 |
| Recommendation | Strong Buy (1.18) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.71 | $-0.96 | $-0.57 | — | -41.5% | 0↑ 1↓ | $0.0B | 0.0% | 4 |
| Next Q 2026-09-30 |
$-0.76 | $-1.09 | $-0.60 | -45.7% | -37.7% | 0↑ 1↓ | $0.0B | 0.0% | 4 |
| Current FY 2026-12-31 |
$-3.10 | $-3.72 | $-2.58 | — | -47.5% | 0↑ 1↓ | $0.0B | 0.0% | 3 |
| Next FY 2027-12-31 |
$-2.94 | $-3.29 | $-2.23 | 5.1% | -29.1% | 0↑ 2↓ | $0.0B | 0.0% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.708 | |
| 7d ago | $-0.535 | -0.172 |
| 30d ago | $-0.500 | -0.208 |
| 60d ago | $-0.420 | -0.288 |
| 90d ago | $-0.420 | -0.288 |
6 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 18, 2026 | Baird | MAINTAIN | Outperform | Outperform |
| May 14, 2026 | Wedbush | MAINTAIN | Neutral | Neutral |
| May 11, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 22, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Apr 2, 2026 | Baird | MAINTAIN | Outperform | Outperform |
| Apr 2, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 2, 2026 | Jones Trading | MAINTAIN | Buy | Buy |
| Apr 2, 2026 | Wedbush | MAINTAIN | Neutral | Neutral |
| Apr 2, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Mar 18, 2026 | Baird | MAINTAIN | Outperform | Outperform |
| Mar 17, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Mar 17, 2026 | Wedbush | MAINTAIN | Neutral | Neutral |
| Feb 17, 2026 | BTIG | MAINTAIN | Buy | Buy |
| Jan 5, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 7 | 7 | 2 | 0 | 0 | 88% | |
| Apr 1, 2026 | 7 | 7 | 2 | 0 | 0 | 88% | |
| Mar 1, 2026 | 7 | 7 | 2 | 0 | 0 | 88% | |
| Feb 1, 2026 | 7 | 7 | 2 | 0 | 0 | 88% | |
| Jan 1, 2026 | 7 | 7 | 2 | 0 | 0 | 88% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Apr 17, 2026
Clinical Trial
PD, PK, and Safety of ALTO-203 in Patients With MDD
Phase Phase 2 — COMPLETED
Apr 2, 2026
short_interest
FTD: ANRO — 71,537 shares ($1.7M) failed to deliver
Settlement: 20260402, Price: $23.41, FTD Value: $1,674,681.17, ALTO NEUROSCIENCE INC
Mar 20, 2026
earnings_calendar
ANRO Q4 2025 Earnings After Market Close — 2026-03-20